Vixtimotamab
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) [1].
Product Specifications
CAS Number
2243775-32-6
Product Name Alternative
AMV-564; TandAb T564
UNSPSC
12352203
Target
Transmembrane Glycoprotein
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vixtimotamab.html
Purity
97.29
Solubility
H2O
Smiles
[Vixtimotamab]
Molecular Weight
(103.14 kDa)
References & Citations
[1]Reusch U, et al. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res. 2016 Dec 1;22 (23) :5829-5838.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740177-100 1x 100 µL
CD50 (ICAM-3) (101-1D2), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040630-500 1x 500 µL
Mucin 1 / EMA / Episialin / CD227 (VU-2G7), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740276-100 1x 100 µL
TAG-72 / CA72.4 (B72.3), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880499-100 1x 100 µL
Cytokeratin 14 (LL002), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470639-500 1x 500 µL
CD31 / PECAM-1 (JC/70A), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details